Evelo Biosciences to Present at 2021 Jefferies London Healthcare Conference
Evelo Biosciences (Nasdaq: EVLO) will host a fireside chat at the Jefferies London Healthcare Conference on November 16, 2021, at 6:20 a.m. ET. The event will highlight Evelo's innovative SINTAX™ medicines, aimed at treating inflammatory diseases and cancers through orally delivered therapies. A live audio webcast will be available on the company's website, with replays accessible for 30 days. Evelo is progressing four product candidates designed to positively impact immune and neurological systems, reinforcing its commitment to developing effective and affordable treatments.
- None.
- None.
CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that management will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th, 2021 at 6:20 a.m. ET (11:20 a.m. GMT).
A live audio webcast of the presentation will be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. A replay of the webcast will be available for approximately 30 days following the presentation.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Contacts
Investors:
Kendra Sweeney, 239-877-7474
ksweeney@evelobio.com
Media:
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com
FAQ
When is Evelo Biosciences presenting at the Jefferies London Healthcare Conference?
How can I listen to Evelo's presentation at the conference?
What is the focus of Evelo Biosciences' product candidates?
Which product candidates is Evelo currently developing?
How long will the replay of Evelo's conference presentation be available?
